bioLeads collaborats with Biofrontera Pharmaceuticals AG
Heidelberg/Leverkusen: bioLeads GmbH and Biofrontera Pharmaceuticals AG announced today that they have entered into a strategic alliance to discover new lead compounds for CNS diseases and develop them to the clinical trials level. The initial focus of the collaboration will be on the medical indications depression and pain.
Biofrontera’s proprietary technology platform will be utilized to identify and validate active and bioavailable compounds whilst bioLeads will provide its unique microbial chemical entity li-braries, plant derived compounds and bioassay-screening platform. Biofrontera’s expression profiling engine will then be used to substantiate these lead compounds in terms of target selectivity, biological activity profile and time course of action. Further iterative rounds of testing at bioLeads and Biofrontera will then lead to drug candidates to be licensed out to global industrial partners or to be brought to the market by the two partners themselves.
This partnership will not only synergistically combine the core strengths of bioLeads and Biofrontera, but will also permit both parties to maintain and expand their present collabora-tions with other pharmaceutical partners.
Other news from the department business & finance
